Evidence map›Paper›PMID 41467552›Full record

ArticleCancer science2026

Expression of the CXCR4 S338X Variant Improves Anti-Leukemia Efficacy of Anti-CD19 CAR-T Cells.

Yushu Mao, Xiaodan Wang, Chun-Hui Jin, Zhifeng Wei, Qinghao Ding, Ke-Ke Zhang, Bo-Wen Dong, Kai-Wen Zheng, Yufei Hou, Tao Zhang and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yushu MaoKey Laboratory of Organ Regeneration and Transplantation of the Ministry of Education, the First Hospital of Jilin University, Changchun, Jilin, China.
Xiaodan WangKey Laboratory of Organ Regeneration and Transplantation of the Ministry of Education, the First Hospital of Jilin University, Changchun, Jilin, China.
Chun-Hui JinKey Laboratory of Organ Regeneration and Transplantation of the Ministry of Education, the First Hospital of Jilin University, Changchun, Jilin, China.
Zhifeng WeiKey Laboratory of Organ Regeneration and Transplantation of the Ministry of Education, the First Hospital of Jilin University, Changchun, Jilin, China.
Qinghao DingKey Laboratory of Organ Regeneration and Transplantation of the Ministry of Education, the First Hospital of Jilin University, Changchun, Jilin, China.
Ke-Ke ZhangKey Laboratory of Organ Regeneration and Transplantation of the Ministry of Education, the First Hospital of Jilin University, Changchun, Jilin, China.
Bo-Wen DongKey Laboratory of Organ Regeneration and Transplantation of the Ministry of Education, the First Hospital of Jilin University, Changchun, Jilin, China.
Kai-Wen ZhengKey Laboratory of Organ Regeneration and Transplantation of the Ministry of Education, the First Hospital of Jilin University, Changchun, Jilin, China.
Yufei HouKey Laboratory of Organ Regeneration and Transplantation of the Ministry of Education, the First Hospital of Jilin University, Changchun, Jilin, China.
Tao ZhangKey Laboratory of Organ Regeneration and Transplantation of the Ministry of Education, the First Hospital of Jilin University, Changchun, Jilin, China.
Wen-Jie ZhaoKey Laboratory of Organ Regeneration and Transplantation of the Ministry of Education, the First Hospital of Jilin University, Changchun, Jilin, China.
Zheng HuKey Laboratory of Organ Regeneration and Transplantation of the Ministry of Education, the First Hospital of Jilin University, Changchun, Jilin, China.ORCID https://orcid.org/0000-0001-8310-4224
Yong-Guang YangKey Laboratory of Organ Regeneration and Transplantation of the Ministry of Education, the First Hospital of Jilin University, Changchun, Jilin, China.

Funding

Human Resource and Social Security Department of Jilin Province 2022DJ02Jilin University (Bethune Medical Department) 2022/2024JBGS01National Key Research and Development Program of China 2021YFA1100700National Natural Science Foundation of China 82171758National Natural Science Foundation of China 82241224National Natural Science Foundation of China 8249100021National Natural Science Foundation of China W2441022Science and Technology Development of Jilin Province 20230505029ZP
6 · The paper itself

Abstract

Chimeric antigen receptor T (CAR-T) cell therapy has demonstrated remarkable success in treating hematological malignancies; however, antigen-positive relapse remains a significant obstacle to achieving sustained remission in B-cell acute lymphoblastic leukemia (B-ALL). To enhance the therapeutic efficacy of anti-CD19 CAR (CAR19)-T cells, we overexpressed CXCR4 in CAR19-T cells to improve their trafficking to bone marrow (BM), a key sanctuary for minimal residual disease. We engineered CAR19-T cells with overexpression of wild-type CXCR4 (CAR19/CXCR4

Indexed as

Antigens, CD19Immunotherapy, AdoptiveReceptors, Chimeric AntigenReceptors, CXCR4T-LymphocytesAnimalsCell Line, TumorChemokine CXCL12FemaleHumansMiceXenograft Model Antitumor AssaysAntigens, CD19Chemokine CXCL12CXCR4 protein, humanReceptors, Chimeric AntigenReceptors, CXCR4B‐cell acute lymphoblastic leukemiabone marrowchimeric antigen receptorCXCR4 S338Xminimal residual disease

Identifiers

PMID41467552
PMCPMC12951118

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.